Study Shows Intradigm’s RNAi Nanoplex Technology To Be Effective Systemic SiRNA Delivery Platform For The Treatment Of Various Cancer Models

Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, announced study results that demonstrated the company’s RNAi Nanoplex (NPX) delivery technology platform is capable of effectively delivering small interfering RNAs (siRNAs) targeting both vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) pathways, two clinically validated pathways in the treatment of various cancers.

More: continued here

Filed under: IT / Internet / E-mail on April 17th, 2008